WO2018169314A1 - Timbre d'hydrogel - Google Patents
Timbre d'hydrogel Download PDFInfo
- Publication number
- WO2018169314A1 WO2018169314A1 PCT/KR2018/003011 KR2018003011W WO2018169314A1 WO 2018169314 A1 WO2018169314 A1 WO 2018169314A1 KR 2018003011 W KR2018003011 W KR 2018003011W WO 2018169314 A1 WO2018169314 A1 WO 2018169314A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- hydrogel patch
- spinal cord
- hydrogel
- laminin
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
Definitions
- spinal spinal cord Damage to the central nervous system (spinal spinal cord) involves psychological as well as medical disorders of motor and urinary disorders.
- spinal cord injury treatment surgical treatment, steroid-based drug treatment such as methylprednisolone, or rehabilitation are being performed.
- steroid-based drug treatment such as methylprednisolone
- rehabilitation is being performed.
- this is only a treatment to alleviate the impairment caused by nerve damage, and there is no fundamental spinal nerve regeneration treatment for impaired spinal nerve regeneration.
- the hydrogel patch or composition can be one that has an intermediate property between a solid and a liquid.
- the hydrogel patch or composition may be amorphous, spherical, hemispherical, discotic, or cylindrical.
- the diameter of the hydrogel patch may be 0.05 mm to 10 cm, 0.1 mm to 5 cm, 0.1 mm to 3 cm, or 0.2 mm to 1.5 cm, and may be provided in such size or shape.
- the hydrogel patch may be modified in conformity with the shape of the injury site by applying, implanting, attaching, or contacting the target site (for example, tissue damage site).
- the hydrogel patch or composition can be porous.
- the surface of the hydrogel patch may have porosity (micropores).
- the hydrogel patch according to one embodiment has a porosity, thereby enhancing interaction between the active materials.
- the fibrin or fibrinogen is at a concentration of 0.5 to 20 mg / ml, 0.8 to 16 mg / ml, 0.8 to 12 mg / ml, 1.0 to 10 mg / ml, 2 to 8 mg / ml, or 4 to 8 mg / ml. May be included.
- the neuronal growth factor may be a brain-derived neurotropic factor (BDNF), a cellular cell derived neurotropic factor (GDNF), a ciliary neurotropic factor (CNTF), a basic fibroblast growth factor (bFGF), a cyclic adenocyne monophosphate (cAMP), or a neurotropin (NT).
- BDNF brain-derived neurotropic factor
- GDNF cellular cell derived neurotropic factor
- CNTF ciliary neurotropic factor
- bFGF basic fibroblast growth factor
- cAMP cyclic adenocyne monophosphate
- NT neurotropin
- Another aspect is fibrinogen; Laminin or laminin derived peptides; And thrombin added to a composition in a sol (Sol) state comprising hyaluronic acid or a pharmaceutically acceptable salt thereof.
- the method may further comprise formulating a cell growth factor in the sol state composition.
- FIG. 1 is a view showing a hydrogel patch manufacturing method and a hydrogel patch of various sizes of 0.3 mm to 0.8 mm according to an embodiment.
- Hyaluronic acid (Sigma, 53747) 0.1 mg / ml, 0.5 mg / ml or 1 mg / ml;
- recombinant Human BDNF (Peprotech, 450-02) 10 ng / ml, recombinant Human GDNF (Peprotech, 450-10) 10 ng / ml, recombinant Human NT-3 (Peprotech, 450-03), 5 ng / ml, db- cAMP (Sigma, D0260) 1 uM, T3 (Sigma, T6397) 60 ng / ml, recombinant Human sonic hedgehog (SHH; Peprotech, 100-45) 50 ng / ml, recombinant Human PDGF-AA (Peprotech, 100-13A- 100), recombinant Human FGF-basic (Peprotech, 100-18B) 10 ng / ml and recombinant Human VEGF165 (Peprotech, 100-20) 20 ng / ml.
- neuronal cells Tuj1 and astrocytes (GFAP) were observed using an inverted fluorescence microscope (Leica, DMI 3000B) attached with a digital monochrome camera (Leica, DFC345 FX). Images observed with inverted fluorescence microscopy were counted by counting the number of neurons or astrocytes using ImageJ (National Institutes of Health (http://rsb.info.nih.gov/ij) software).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880002192.6A CN109526207B (zh) | 2017-03-14 | 2018-03-14 | 水凝胶贴片 |
EP18766653.2A EP3449913B1 (fr) | 2017-03-14 | 2018-03-14 | Timbre d'hydrogel |
US16/305,039 US20190167850A1 (en) | 2017-03-14 | 2018-03-14 | Hydrogel patch |
JP2018562205A JP6750042B2 (ja) | 2017-03-14 | 2018-03-14 | ヒドロゲルパッチ |
CA3029189A CA3029189C (fr) | 2017-03-14 | 2018-03-14 | Timbre d'hydrogel |
AU2018236629A AU2018236629B2 (en) | 2017-03-14 | 2018-03-14 | Hydrogel patch |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170032019 | 2017-03-14 | ||
KR10-2017-0032019 | 2017-03-14 | ||
KR1020180029857A KR102056391B1 (ko) | 2017-03-14 | 2018-03-14 | 하이드로젤 패치 |
KR10-2018-0029857 | 2018-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018169314A1 true WO2018169314A1 (fr) | 2018-09-20 |
Family
ID=63523615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/003011 WO2018169314A1 (fr) | 2017-03-14 | 2018-03-14 | Timbre d'hydrogel |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018169314A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070010831A1 (en) * | 2002-08-01 | 2007-01-11 | Romero-Ortega Mario I | Biomimetic biosynthetic nerve implant |
KR20110002741A (ko) * | 2009-07-02 | 2011-01-10 | 아주대학교산학협력단 | 체내 주입형 하이드로젤 및 이의 생의학적 용도 |
-
2018
- 2018-03-14 WO PCT/KR2018/003011 patent/WO2018169314A1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070010831A1 (en) * | 2002-08-01 | 2007-01-11 | Romero-Ortega Mario I | Biomimetic biosynthetic nerve implant |
KR20110002741A (ko) * | 2009-07-02 | 2011-01-10 | 아주대학교산학협력단 | 체내 주입형 하이드로젤 및 이의 생의학적 용도 |
Non-Patent Citations (6)
Title |
---|
"Remington's Pharmaceutical Sciences", 1995 |
ARULMOLI, J. ET AL.: "Combination Scaffolds of Salmon Fibrin, Hyaluronic Acid, and Laminin for Human Neural Stem Cell and Vascular Tissue Engineering", ACTA BIOMATERIALIA, vol. 43, 2016, pages 122 - 138, XP055548151 * |
KIM JB ET AL., NAT PROTOC, 2009 |
LEE, F. ET AL.: "Formation and Stability of Interpenetrating Polymer Network Hydrogels Consisting of Fibrin and Hyaluronic Acid for Tissue Engineering", ACTA BIOMATERIALIA, vol. 9, 2013, pages 5143 - 5152, XP055450790 * |
PARK, J. ET AL.: "Nerve Regeneration Following Spinal Cord Injury Using Matrix Metalloproteinase-sensitive, Hyaluronic Acid-based Biomimetic Hydrogel Scaffold Containing Brain-derived Neurotrophic Factor", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 93, 2010, pages 1091 - 1099, XP055560185 * |
See also references of EP3449913A4 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102078790B1 (ko) | 히알루론산을 포함하는 척수 손상의 치료를 위한 하이드로젤 패치 및 약학적 조성물 | |
Wang et al. | Promoting engraftment of transplanted neural stem cells/progenitors using biofunctionalised electrospun scaffolds | |
Zou et al. | Aligned collagen scaffold combination with human spinal cord-derived neural stem cells to improve spinal cord injury repair | |
Thompson et al. | Effect of hyaluronic acid hydrogels containing astrocyte-derived extracellular matrix and/or V2a interneurons on histologic outcomes following spinal cord injury | |
Silva et al. | The effects of peptide modified gellan gum and olfactory ensheathing glia cells on neural stem/progenitor cell fate | |
Johnson et al. | Identification of barriers to retinal engraftment of transplanted stem cells | |
Liu et al. | Chitosan conduits combined with nerve growth factor microspheres repair facial nerve defects | |
CA3004450A1 (fr) | Vesicules extracellulaires de cellules neurales | |
EP2233150A2 (fr) | Erythropoietin pour utilisation dans la guérison de blessures ou la transplantation de cellules | |
Tang et al. | The effects of controlled release of neurotrophin-3 from PCLA scaffolds on the survival and neuronal differentiation of transplanted neural stem cells in a rat spinal cord injury model | |
Yao et al. | Chitosan-based thermosensitive composite hydrogel enhances the therapeutic efficacy of human umbilical cord MSC in TBI rat model | |
CA2582073A1 (fr) | Traitement de deficits neurologiques dans le striatum ou la substance noire pars compacta | |
US8846394B2 (en) | Treatment of neurological deficits in the striatum or substanta nigra pars compacta | |
Cen et al. | Research progress of stem cell therapy for endometrial injury | |
WO2018169314A1 (fr) | Timbre d'hydrogel | |
US20160120911A1 (en) | Transplantation of cells into the nasal cavity and the subarachnoid cranial space | |
KR20210132638A (ko) | 신경계 세포 요법 | |
Ramesh et al. | Biodegradable nanofiber coated human umbilical cord as nerve scaffold for sciatic nerve regeneration in albino Wistar rats | |
Kandalam | Pharmacologically active microcarriers delivering brainderived neurotrophic factor combined to adult mesenchymal stem cells: novel approach for the treatment of spinal cord injury | |
Shanbhag | Development of a multi-functional construct for central nervous system repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018562205 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18766653 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018766653 Country of ref document: EP Effective date: 20181126 |
|
ENP | Entry into the national phase |
Ref document number: 3029189 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018236629 Country of ref document: AU Date of ref document: 20180314 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |